At present, whether AAT levels are above or below the 11-μM protective threshold should not in itself guide treatment decisions, and in the absence of evidence, this should possibly be based on the accumulation of other risk factors including younger age of symptom onset, smoking status, confirmed emphysema on CT and its progression despite smoking cessation. This evidence concerns the gene SERPINA1 and pulmonary emphysema.